FDA investigating Elevidys safety; Nektar shares spike on eczema data

The agency said it will evaluate whether regulatory action is needed after investigating the deaths of two patients treated with Sarepta's therapy.

A longer ‘winter’: Public funding slowdown heightens pressure on biotech startups

A dramatic pullback in public biotech investment catalyzed by economic and regulatory upheaval is putting even more stress on startups navigating a yearslong downturn.

The cancer drugs that could best Keytruda

Vor, with new CEO, changes course to target autoimmune disease

The biotech, which earlier this year laid off nearly all of its staff, also announced a PIPE that will hand it $175 million in new funding.

Lexeo to help launch spinout around RNA drugs for the heart

Backed by Perceptive Xontogeny Venture Funds and venBio Partners, the new biotech will make genetic medicines that don’t rely on viral vectors.

‘Superbabies’ Startup Seeks Funds for Controversial Gene Editing Push

Off-the-shelf stem cell therapy for type 1 diabetes yields more positive results

Cash-strapped Sangamo seeks partner for Fabry gene therapy